A 40-75-year-old with LDL 120 mg/dl and 10-year PCE risk 5.0-7.5%: which approach is appropriate?

Prepare for the ACCSAP CCKE Coronary Artery Disease Test. Use flashcards and multiple choice questions, complete with hints and explanations. Ensure success on your test!

Multiple Choice

A 40-75-year-old with LDL 120 mg/dl and 10-year PCE risk 5.0-7.5%: which approach is appropriate?

Explanation:
The main idea here is how to choose statin intensity for primary prevention based on age, LDL, and estimated ASCVD risk. Even though the 10-year ASCVD risk is in the intermediate range (about 5–7.5%), starting a high‑intensity statin is chosen to maximize absolute risk reduction by achieving large LDL lowering. High‑intensity statins typically lower LDL by about 50% or more, which translates into a meaningful decrease in future ASCVD events for many middle‑aged adults, especially when LDL is not low and the lifetime risk remains substantial. In this scenario, initiating high‑intensity statin now provides the strongest potential benefit and aligns with a proactive approach to reduce future events, with the option to use risk discussion and, if uncertainty persists, risk stratification tools like CAC scoring to refine decisions later. While lifestyle modification remains important, it alone is usually not enough to achieve the level of risk reduction targeted in intermediate-risk individuals, which is why early initiation of a potent statin is considered appropriate here. If you were thinking of delaying therapy, or relying only on lifestyle, that would under-treat the patient's risk. CAC scoring can be useful as a supplementary step if the decision is uncertain after discussion, but it is not a prerequisite to start treatment in this context.

The main idea here is how to choose statin intensity for primary prevention based on age, LDL, and estimated ASCVD risk. Even though the 10-year ASCVD risk is in the intermediate range (about 5–7.5%), starting a high‑intensity statin is chosen to maximize absolute risk reduction by achieving large LDL lowering. High‑intensity statins typically lower LDL by about 50% or more, which translates into a meaningful decrease in future ASCVD events for many middle‑aged adults, especially when LDL is not low and the lifetime risk remains substantial.

In this scenario, initiating high‑intensity statin now provides the strongest potential benefit and aligns with a proactive approach to reduce future events, with the option to use risk discussion and, if uncertainty persists, risk stratification tools like CAC scoring to refine decisions later. While lifestyle modification remains important, it alone is usually not enough to achieve the level of risk reduction targeted in intermediate-risk individuals, which is why early initiation of a potent statin is considered appropriate here.

If you were thinking of delaying therapy, or relying only on lifestyle, that would under-treat the patient's risk. CAC scoring can be useful as a supplementary step if the decision is uncertain after discussion, but it is not a prerequisite to start treatment in this context.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy